Oppenheimer Begins Coverage on Savara (NASDAQ:SVRA)

Research analysts at Oppenheimer started coverage on shares of Savara (NASDAQ:SVRA) in a research note issued on Friday. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Oppenheimer’s price target would indicate a potential upside of 118.47% from the stock’s current price.

SVRA has been the subject of a number of other reports. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Finally, William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Savara Stock Performance

NASDAQ SVRA traded up $0.10 during trading hours on Friday, reaching $5.04. The stock had a trading volume of 100,560 shares, compared to its average volume of 1,569,869. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The stock has a fifty day moving average of $5.51 and a 200 day moving average of $5.33. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.85 and a current ratio of 11.85. The stock has a market cap of $1.03 billion, a P/E ratio of -9.51 and a beta of 0.32.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Sell-side analysts predict that Savara will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Large investors have recently modified their holdings of the business. Rhumbline Advisers raised its position in shares of Savara by 10.8% in the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after buying an additional 16,634 shares during the last quarter. Prudential Financial Inc. acquired a new position in Savara during the second quarter worth about $30,000. XTX Topco Ltd purchased a new stake in Savara during the 2nd quarter valued at about $201,000. Invesco Ltd. grew its stake in Savara by 35.4% during the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after acquiring an additional 31,633 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after acquiring an additional 6,449 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.